Moderna, Inc. SEC filings MRNA

Moderna, Inc. has 1,002 filings in SEC EDGAR's recent list, going back to Mar 30, 2021. Its latest annual report, Form ARS, was filed on Mar 16, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Jul 31, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 30, 2026 (officer or director change, regulation fd disclosure). The company's fiscal year ends on December 31.

Form Description Filed Period
ARS Annual report to shareholders Mar 16, 2026 Dec 31, 2025
10-K Annual report Feb 20, 2026 Dec 31, 2025
ARS Annual report to shareholders Mar 11, 2025 Dec 31, 2024
10-K Annual report Feb 21, 2025 Dec 31, 2024
ARS Annual report to shareholders Mar 15, 2024 Dec 31, 2023
10-K Annual report Feb 23, 2024 Dec 31, 2023
ARS Annual report to shareholders Feb 27, 2023 Dec 31, 2022
10-K Annual report Feb 24, 2023 Dec 31, 2022
10-K Annual report Feb 25, 2022 Dec 31, 2021

Showing 9 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
MRNA (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Cambridge, MA
SEC filer status
Large accelerated filer
SEC CIK
1682852
Former names
Moderna Therapeutics, Inc. (until Aug 24, 2016)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.